MedTrace Logo

Resveratrol With or Without Piperine to Enhance Plasma Levels of Resveratrol

NCT01324089 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2019-12-13

No results posted yet for this study

Summary

There is some evidence that when resveratrol (a substance which is found in red grapes, peanuts and chocolate) is combined with Piperine (a substance found in pepper) it is more effective in fighting cancer. The purpose of this study is to see if resveratrol in combination with piperine is more effective than taking resveratrol alone. Since investigators don't know what dose of piperine to use in combination with resveratrol, two different doses of piperine will be studied.

Twenty-four participants, equal numbers of males and females, will receive a single dose of resveratrol (2.5 grams) without piperine, resveratrol (2.5 grams) with piperine (5 mg), or resveratrol (2.5 grams) with piperine (25 mg).

Conditions

  • Focus of the Study: Normal Volunteers

Interventions

DIETARY_SUPPLEMENT

Resveratrol

Resveratrol 2.5 grams

DIETARY_SUPPLEMENT

Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose

Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose

DIETARY_SUPPLEMENT

Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose

Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Howard H Bailey, MD · University of Wisconsin, Madison

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2011-11-30
Completion
2012-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01324089 on ClinicalTrials.gov